Guggenheim Begins Coverage on Zevra Therapeutics (NASDAQ:ZVRA)

Guggenheim started coverage on shares of Zevra Therapeutics (NASDAQ:ZVRA - Free Report) in a research report released on Monday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $20.00 price target on the stock.

Several other equities research analysts also recently weighed in on the stock. JMP Securities began coverage on shares of Zevra Therapeutics in a research note on Tuesday, September 24th. They set an outperform rating and a $17.00 target price for the company. Canaccord Genuity Group decreased their price objective on Zevra Therapeutics from $24.00 to $22.00 and set a buy rating for the company in a research report on Wednesday, September 18th. Cantor Fitzgerald reissued an overweight rating on shares of Zevra Therapeutics in a report on Tuesday, October 1st. Maxim Group increased their price target on Zevra Therapeutics from $18.00 to $25.00 and gave the stock a buy rating in a report on Tuesday, September 24th. Finally, William Blair upgraded shares of Zevra Therapeutics to a strong-buy rating in a research report on Friday, August 30th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Zevra Therapeutics presently has an average rating of Buy and an average price target of $20.83.

Zevra Therapeutics Stock Up 8.2 %

Shares of Zevra Therapeutics stock traded up $0.59 during trading hours on Monday, hitting $7.79. The company had a trading volume of 1,455,056 shares, compared to its average volume of 521,118. The company has a debt-to-equity ratio of 1.80, a current ratio of 2.00 and a quick ratio of 2.00. The company's 50-day moving average is $7.24 and its two-hundred day moving average is $5.79. The company has a market cap of $326.03 million, a P/E ratio of -5.74 and a beta of 1.94. Zevra Therapeutics has a twelve month low of $3.89 and a twelve month high of $8.95.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.01). The firm had revenue of $4.45 million during the quarter, compared to analysts' expectations of $4.08 million. Zevra Therapeutics had a negative net margin of 274.10% and a negative return on equity of 124.85%. During the same period in the previous year, the firm posted ($0.15) earnings per share. Analysts anticipate that Zevra Therapeutics will post -1.59 earnings per share for the current fiscal year.

Insider Activity at Zevra Therapeutics

In related news, Director Thomas Anderson bought 10,000 shares of the stock in a transaction on Tuesday, July 16th. The shares were bought at an average cost of $6.81 per share, for a total transaction of $68,100.00. Following the completion of the transaction, the director now owns 20,000 shares of the company's stock, valued at $136,200. This represents a 100.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders purchased 22,000 shares of company stock worth $140,340 over the last 90 days. Company insiders own 2.40% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company boosted its position in shares of Zevra Therapeutics by 15.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company's stock worth $91,000 after buying an additional 2,452 shares in the last quarter. Rhumbline Advisers raised its stake in Zevra Therapeutics by 17.9% in the 2nd quarter. Rhumbline Advisers now owns 56,874 shares of the company's stock valued at $279,000 after purchasing an additional 8,619 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new position in Zevra Therapeutics in the 1st quarter valued at about $64,000. SG Americas Securities LLC acquired a new position in shares of Zevra Therapeutics in the third quarter valued at approximately $105,000. Finally, Jacobs Levy Equity Management Inc. raised its holdings in Zevra Therapeutics by 102.4% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company's stock valued at $201,000 after acquiring an additional 17,557 shares during the last quarter. Hedge funds and other institutional investors own 35.03% of the company's stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.